NASDAQ:AIMT - Aimmune Therapeutics News Headlines

$18.99
+0.21 (+1.12 %)
(As of 07/17/2019 04:00 PM ET)
Today's Range
$18.69
Now: $18.99
$19.04
50-Day Range
$18.37
MA: $20.07
$21.49
52-Week Range
$16.95
Now: $18.99
$36.12
Volume31,904 shs
Average Volume604,084 shs
Market Capitalization$1.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.06

Headlines

Aimmune Therapeutics (NASDAQ AIMT) News Headlines

Source:
DateHeadline
Aimmune Therapeutics (NASDAQ:AIMT) Coverage Initiated by Analysts at Roth CapitalAimmune Therapeutics (NASDAQ:AIMT) Coverage Initiated by Analysts at Roth Capital
www.americanbankingnews.com - July 12 at 4:47 PM
Heres Why Aimmune Therapeutics Fell 7% TodayHere's Why Aimmune Therapeutics Fell 7% Today
finance.yahoo.com - July 12 at 8:36 AM
Here's Why Aimmune Therapeutics Fell 7% TodayHere's Why Aimmune Therapeutics Fell 7% Today
finance.yahoo.com - July 12 at 8:36 AM
Aimmune down 7% on cautious ICER report on peanut allergy treatmentsAimmune down 7% on cautious ICER report on peanut allergy treatments
seekingalpha.com - July 11 at 6:11 PM
Aimmune Therapeutics (NASDAQ:AIMT) PT Set at $79.00 by WedbushAimmune Therapeutics (NASDAQ:AIMT) PT Set at $79.00 by Wedbush
www.americanbankingnews.com - July 11 at 6:01 PM
Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final Report on AR101 for Peanut AllergyAimmune Statement on Institute for Clinical and Economic Review (ICER) Final Report on AR101 for Peanut Allergy
finance.yahoo.com - July 11 at 8:33 AM
Aimmune Therapeutics Inc (NASDAQ:AIMT) Given Average Rating of "Buy" by BrokeragesAimmune Therapeutics Inc (NASDAQ:AIMT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 10 at 2:29 AM
Aimmune Therapeutics (NASDAQ:AIMT) Receives Outperform Rating from WedbushAimmune Therapeutics (NASDAQ:AIMT) Receives Outperform Rating from Wedbush
www.americanbankingnews.com - July 2 at 9:16 AM
Aimmune Therapeutics Inc (NASDAQ:AIMT) Expected to Announce Earnings of -$0.91 Per ShareAimmune Therapeutics Inc (NASDAQ:AIMT) Expected to Announce Earnings of -$0.91 Per Share
www.americanbankingnews.com - June 28 at 6:15 PM
Aimmune submits MAA for AR101 in EuropeAimmune submits MAA for AR101 in Europe
seekingalpha.com - June 28 at 8:37 AM
Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut AllergyAimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy
finance.yahoo.com - June 28 at 8:37 AM
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Is Expected To BreakevenAimmune Therapeutics, Inc. (NASDAQ:AIMT) Is Expected To Breakeven
finance.yahoo.com - June 20 at 7:31 PM
What Makes Aimmune Therapeutics (AIMT) a New Buy StockWhat Makes Aimmune Therapeutics (AIMT) a New Buy Stock
finance.yahoo.com - June 13 at 1:20 PM
Aimmune to Present at the JMP Securities Life Sciences ConferenceAimmune to Present at the JMP Securities Life Sciences Conference
finance.yahoo.com - June 12 at 10:47 AM
Aimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER MeetingAimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting
finance.yahoo.com - June 11 at 9:01 AM
Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare ConferenceAimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference
finance.yahoo.com - June 5 at 8:28 AM
Aimmune reports positive AR101 data in peanut allergy studyAimmune reports positive AR101 data in peanut allergy study
seekingalpha.com - June 4 at 6:38 PM
Data from Two Studies Confirm Quality of Life and Psychosocial Burden of Living with Peanut AllergyData from Two Studies Confirm Quality of Life and Psychosocial Burden of Living with Peanut Allergy
finance.yahoo.com - June 4 at 6:38 PM
New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One YearNew Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year
finance.yahoo.com - June 4 at 8:39 AM
Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut AllergyPivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy
finance.yahoo.com - June 2 at 8:27 AM
Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 CongressAimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress
finance.yahoo.com - May 24 at 8:37 AM
New Study Shows More Than Half of Teens with Peanut Allergy Visited the E.R., More Than One-Third Required Hospitalization Due to Accidental Exposure to PeanutNew Study Shows More Than Half of Teens with Peanut Allergy Visited the E.R., More Than One-Third Required Hospitalization Due to Accidental Exposure to Peanut
finance.yahoo.com - May 21 at 7:15 PM
Aimmune: Delivering The Silver Bullets For Various Food AllergiesAimmune: Delivering The Silver Bullets For Various Food Allergies
seekingalpha.com - May 16 at 7:35 PM
Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut AllergyAimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy
www.marketwatch.com - May 16 at 9:45 AM
FDA sets September 13 as meeting date for Aimmune Therapeutics AR101FDA sets September 13 as meeting date for Aimmune Therapeutics' AR101
seekingalpha.com - May 16 at 9:45 AM
Biotech News Recap: Key NASH Readout Coming Up For CymaBay TherapeuticsBiotech News Recap: Key NASH Readout Coming Up For CymaBay Therapeutics
seekingalpha.com - May 10 at 8:38 AM
Aimmune Therapeutics, Inc. (AIMT) Q1 2019 Earnings Call TranscriptAimmune Therapeutics, Inc. (AIMT) Q1 2019 Earnings Call Transcript
finance.yahoo.com - May 9 at 8:35 AM
Edited Transcript of AIMT earnings conference call or presentation 8-May-19 8:30pm GMTEdited Transcript of AIMT earnings conference call or presentation 8-May-19 8:30pm GMT
finance.yahoo.com - May 9 at 8:35 AM
Aimmune Therapeutics to Host Conference Call and Webcast to DiscussFirst Quarter 2019 Financial Results and Recent Operational HighlightsAimmune Therapeutics to Host Conference Call and Webcast to DiscussFirst Quarter 2019 Financial Results and Recent Operational Highlights
www.marketwatch.com - May 1 at 8:29 AM
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Recent Operational HighlightsAimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights
finance.yahoo.com - May 1 at 8:29 AM
Aimmune Therapeutics is Now Oversold (AIMT)Aimmune Therapeutics is Now Oversold (AIMT)
www.nasdaq.com - April 17 at 7:15 PM
Aimmune Therapeutics to Present at 18th Annual Needham & Company Healthcare ConferenceAimmune Therapeutics to Present at 18th Annual Needham & Company Healthcare Conference
www.marketwatch.com - April 3 at 8:56 AM
Aimmune Therapeutics Could Achieve Regulatory Firsts With Peanut Allergy TreatmentAimmune Therapeutics Could Achieve Regulatory Firsts With Peanut Allergy Treatment
seekingalpha.com - March 27 at 8:42 AM
Aimmune up 9% premarket on successful AR101 studyAimmune up 9% premarket on successful AR101 study
seekingalpha.com - March 25 at 7:20 PM
European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary EndpointEuropean Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint
www.marketwatch.com - March 25 at 7:20 PM
4 Blockbuster Drug Launches to Watch in 20194 Blockbuster Drug Launches to Watch in 2019
finance.yahoo.com - March 24 at 8:05 PM
Aimmune Therapeutics, Inc. Estimate MomentumAimmune Therapeutics, Inc. Estimate Momentum
www.nasdaq.com - March 18 at 7:44 PM
Aimmune down 5% on FDA timeline for AR101Aimmune down 5% on FDA timeline for AR101
seekingalpha.com - March 18 at 7:44 PM
AIMMUNE THERAPEUTICS, INC. AIMT Files An 8-K Other EventsAIMMUNE THERAPEUTICS, INC. AIMT Files An 8-K Other Events
www.marketwatch.com - March 18 at 7:44 PM
U.S. FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut AllergyU.S. FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy
finance.yahoo.com - March 18 at 8:27 AM
Detailed Research: Economic Perspectives on Canopy Growth, Aimmune Therapeutics, Nektar Therapeutics, Workday, Workiva, and MAG Silver — What Drives Growth in Todays Competitive Landscape - GlobeNewswireDetailed Research: Economic Perspectives on Canopy Growth, Aimmune Therapeutics, Nektar Therapeutics, Workday, Workiva, and MAG Silver — What Drives Growth in Today's Competitive Landscape - GlobeNewswire
globenewswire.com - March 6 at 7:25 PM
Aimmune Therapeutics to Participate in Three Investor Conferences in MarchAimmune Therapeutics to Participate in Three Investor Conferences in March
www.marketwatch.com - March 5 at 8:56 AM
Edited Transcript of AIMT earnings conference call or presentation 28-Feb-19 10:00pm GMTEdited Transcript of AIMT earnings conference call or presentation 28-Feb-19 10:00pm GMT
finance.yahoo.com - March 2 at 6:12 PM
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational HighlightsAimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights
finance.yahoo.com - February 28 at 6:52 PM
Aimmune Therapeutics Q4 2018 Earnings PreviewAimmune Therapeutics Q4 2018 Earnings Preview
seekingalpha.com - February 27 at 7:09 PM
Aimmune Therapeutics (AIMT) Presents New AR101 Data at AAAAI - StreetInsider.comAimmune Therapeutics (AIMT) Presents New AR101 Data at AAAAI - StreetInsider.com
www.streetinsider.com - February 25 at 6:53 PM
Aimmune Therapeutics Presents New AR101 Data at AAAAI, Including Demonstrated Reduction in Accidental Exposures to Peanut Requiring TreatmentAimmune Therapeutics Presents New AR101 Data at AAAAI, Including Demonstrated Reduction in Accidental Exposures to Peanut Requiring Treatment
finance.yahoo.com - February 25 at 8:58 AM
First Week of April 18th Options Trading For Aimmune Therapeutics - NasdaqFirst Week of April 18th Options Trading For Aimmune Therapeutics - Nasdaq
www.nasdaq.com - February 22 at 6:55 PM
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational HighlightsAimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
finance.yahoo.com - February 21 at 8:51 AM
Aimmune Therapeutics to Present AR101, OIT and Peanut Allergy Data at 2019 AAAAI Annual MeetingAimmune Therapeutics to Present AR101, OIT and Peanut Allergy Data at 2019 AAAAI Annual Meeting
finance.yahoo.com - February 5 at 8:55 AM
This page was last updated on 7/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel